Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal Indomethacin Versus Diclofenac for Prevention of Post-ERCP Pancreatitis
NCT07071441Recruiting
- Sponsor
- Air Force Medical University
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of indomethacin in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Air Force Medical University. Primary endpoint: Rate of post-ERCP Pancreatitis at 30 days. Started Jun 2025; status: recruiting.
02
Drugs
indomethacin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT07071441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071441.